Cécile Dorange
Bristol-Myers Squibb (United States)
1 paper in the Anchorcite directory, published in 2015, cited 9,473 times in total.
Research topics
- Cancer Immunotherapy and Biomarkers · 1 paper
- Lung Cancer Diagnosis and Treatment · 1 paper
- Lung Cancer Treatments and Mutations · 1 paper
Frequent co-authors
- Hossein Borghaei · 1 paper
- Luis G Paz-Ares · 1 paper
- Leora Horn · 1 paper
- David Robert Spigel · 1 paper
- Martin B. Steins · 1 paper
- Neal Ready · 1 paper
- Laura Q.M. Chow · 1 paper
- Everett E. Vokes · 1 paper
Papers
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 9,473 citations
BACKGROUND: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. METHODS: In this randomized, open-label, international phase 3 study, we assigned patients with nonsquamous non-small-cell lung cancer (NSCLC) that had…
Metadata from OpenAlex (CC0).